| Identification | Back Directory | [Name]
H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH | [CAS]
568565-11-7 | [Synonyms]
QRPRLSHKGPMPA
[ALA13]-APELIN-13
[Ala13]Apelin 13 (human, mouse, rat, bovine)
(ALA13)-APELIN-13 (HUMAN, BOVINE, MOUSE, RAT)
GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA
[Ala13]Apelin-13, human, bovine, mouse, rat (F13A) (2)
H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH
L-Glutaminyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl-L-alanine
L-Alanine, L-glutaminyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl-
(Ala13)-Apelin-13 (human, bovine, mouse, rat) acetate salt H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH acetate salt
(Ala13)-Apelin-13 (human, bovine, mouse, rat) trifluoroacetate salt H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH trifluoroacetate salt
Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala ((2) Due to the presence of a Gln in N-terMinal position this peptide can contain the pyroglutaMic forM) | [Molecular Formula]
C63H107N23O16S | [MDL Number]
MFCD08459499 | [MOL File]
568565-11-7.mol | [Molecular Weight]
1474.73 |
| Chemical Properties | Back Directory | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
powder | [pka]
3.70±0.10(Predicted) | [color ]
white to beige | [Sequence]
Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala |
| Hazard Information | Back Directory | [Uses]
(Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway[1]. | [Biological Activity]
(Ala13)-Apelin-13 corresponds to Apelin-13 with a Phe-to-Ala substitution at the C-terminus (F13A) and functions as an antagonist against apelin-dependent APJ functions both in cultures and in animal studies in vivo. | [in vivo]
(Ala13)-Apelin-13 (1-300 pmol/60 nl; microinjected into the DVC) decreases gastric tone and motility in a dose-dependent manner in rats[1]. | Animal Model: | 250-300 g, Sprague-Dawley rats[1] | | Dosage: | 1-300 pmol/60 nl | | Administration: | Microinjected into the DVC (dorsal vagal complex (DVC) | | Result: | Decreased gastric tone and motility in a dose-dependent manner with D50?≈?27 pmol for both antrum and corpus. |
| [References]
[1] Bülbül M, et al. Apelin-13 inhibits gastric motility through vagal cholinergic pathway in rats. Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G201-G210. DOI:10.1152/ajpgi.00223.2017
[2] O'Harte FPM,et al. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochem Pharmacol. 2017 Dec 15;146:165-173. DOI:10.1016/j.bcp.2017.10.002 |
|
|